| Name | Title | Contact Details |
|---|
resTORbio, Inc. is a clinical stage company, developing medicines to treat aging-related diseases and conditions. resTORbio`s lead program targets the mechanistic target of rapamycin complex 1 (mTORC1) pathway to treat aging-related diseases and conditions. Initially, resTORbio is focused on developing medicines that address conditions caused by immunosenescence, the decline in immune function due to aging. resTORbio has initiated a Phase 2b trial for its lead product candidate, RTB101, evaluating its potential to reduce the incidence of respiratory tract infections (RTI) in elderly individuals at increased risk of RTI-related morbidity and mortality. resTORbio`s lead program is built upon two Phase 2a clinical studies demonstrating promising safety and efficacy results in almost 500 elderly individuals.
A new setpoint for immunometabolism
3 Prime is a Aston, PA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
Diassess Inc. is revolutionizing the way infectious diseases are prevented, diagnosed, and monitored by developing the tools necessary to empower people to become knowledgeable about their health.
PNP Therapeutics is a Birmingham, AL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.